MedTrace Logo

Ischemia- Modified Albumin Levels in the Sudden Hearing Loss

NCT03706183 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2018-10-17

No results posted yet for this study

Summary

To evaluate ischemia-modified albumin levels in these patients to investigate the presence of ischemia in patients presenting with sudden hearing loss.

Conditions

  • Sudden Hearing Loss
  • Ischemia

Interventions

DIAGNOSTIC_TEST

Ischemia-modified albumin

The biomarker was investigated in many studies and it was associated with the ischemia and tissue injury.

DIAGNOSTIC_TEST

Hearing thresholds

The hearing levels will be determined for each group.

Sponsors & Collaborators

  • Yuzuncu Yıl University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2018-12-31
Completion
2019-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03706183 on ClinicalTrials.gov